The invention relates to a composition containing i) a DPP-4 inhibitor selected from an extract of
dandelion (Taraxacum officinale), an extract of
white mulberry (Morus alba), an extract of
bitter melon (
Momordica charantia), a
hydrolysate of
yeast (
Saccharomyces cerevisiae), an extract of garlic (
Allium sativum), an extract of grape (
Vitis vinifera), an extract of turmeric (
Curcuma longa), an extract of horseradish tree (
Moringa oleifera) and an extract of fenugreek (
Trigonella foenum-graecum); and ii) a GLP-1 analogue selected from a
hydrolysate of
yeast (
Saccharomyces cerevisiae), a
white mulberry (Morus alba) extract, a yerba mate (Ilex paraguariensis) extract, an Arabica coffee (
Coffea arabica) extract, a purslane (
Portulaca oleracea) extract, a
bitter melon (
Momordica charantia) extract, a lager flower (
Lagerstroemia speciosa) extract, an apple (
Malus domestica) extract, a cinnamon (
Cinnamomum verum) extract and a fenugreek (
Trigonella foenum-graecum) extract; and iii) a GLP-1
secretion enhancer selected from
inulin,
gum arabic, an extract of
bitter melon (
Momordica charantia), an extract of purslane (
Portulaca oleracea), an extract of common barberry (
Berberis vulgaris), an extract of Arabica coffee (
Coffea arabica), an extract of Siberian angelica (
Angelica dahurica), an extract of turmeric (
Curcuma longa) and an extract of fenugreek (
Trigonella foenum-graecum), where at least one ingredient is selected from each group i)-iii) and a total of at least three different ingredients are selected.